IntelliPharmaCeutics International (NASDAQ: IPCI) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference
IntelliPharmaCeutics International (NASDAQ: IPCI) is a pharmaceutical company that engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. For more information, visit the company's website at www.intellipharmaceutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release…